01544nas a2200325   4500000000100000008004100001260001700042653001500059653001000074653001000084653002100094653001200115653001600127653001100143653001100154653002500165653001100190653002300201653001200224653000900236653001600245653001300261100001500274700001500289245008200304300001100386490000600397520080100403022001401204       1986                            d  c1986 Oct-Dec10aAdolescent10aAdult10aChild10aChild, Preschool10aDapsone10aEthionamide10aFemale10aHumans10aIndian Ocean Islands10aInfant10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aRifampin1 aGrillone S1 aPattyn S R00a[A new plan in the campaign against leprosy in Anjouan. Preliminary results].  a453-600 v43 a<p>Treatment of PB leprosy patients with 10 weekly doses of RMP 600 mg gave a cure rate of 88% or more at 3 years as judged by histopathology. There were no severe neurological complications. The future will show if this regimen also prevents relapses. In MB leprosy a 2 months regimen of daily RMP, ETH, DDS followed by 10 months of daily ETH, DDS with weekly RMP gave excellent clinical and bacteriological results. There were no relapses during 2 and 3 years after the end of therapy among 111 newly diagnosed and previously treated patients (95% confidence interval 3.3%) of whom 67 were new patients (95% confidence interval 5.3%). The hepatotoxicity of this regimen has to be followed closely. The results illustrate the possibility to cure MB leprosy by a treatment of finite duration.</p>  a0001-5938